Hyperglycemic Exacerbation of Ischemia/Reperfusion Injury after Ischemic Insult (R01) | Apply Online

FAQs: NIH PA 07-323 (R01) - Hyperglycemia and Myocardial Ischemia/Reperfusion Injury

What is the focus of NIH funding opportunity PA 07-323?

PA 07-323 is an NIH discretionary grant solicitation using the R01 Research Project Grant mechanism. It focuses on understanding how hyperglycemia (acutely elevated blood glucose) worsens tissue damage during and after an acute myocardial ischemic event, especially during the ischemia/reperfusion phase.

What scientific problem is this opportunity trying to address?

The opportunity is centered on clarifying the biological mechanisms by which high glucose levels intensify myocardial injury when blood flow is restricted (ischemia) and then restored (reperfusion). It highlights that reperfusion itself can trigger additional damage through processes such as oxidative stress, inflammation, endothelial dysfunction, calcium overload, and related pathways, and seeks to understand how hyperglycemia aggravates these processes.

Why is hyperglycemia important in acute myocardial ischemia?

The announcement is framed around the clinical reality that many patients presenting with acute coronary syndromes have stress hyperglycemia or diabetes, and that outcomes are often worse when glucose is elevated at the time of the ischemic insult. This FOA targets the added harm associated with elevated glucose during ischemia and reperfusion.

Is this FOA limited to descriptive or observational studies?

No. While mechanistic understanding is central, the FOA emphasizes moving beyond showing associations. It encourages mechanistic work that identifies actionable targets and then evaluates candidate therapies in well-designed preclinical models where glucose is acutely elevated around the time of ischemia and reperfusion.

What types of studies are especially encouraged?

A key practical emphasis is preclinical testing of new therapeutic interventions intended to reduce ischemia/reperfusion-induced myocardial injury specifically in the context of hyperglycemia. The FOA seeks evidence strong enough to justify future translational steps by demonstrating meaningful reduction in myocardial damage under hyperglycemic conditions and explaining why the intervention works at molecular and physiological levels.

What is meant by the ischemia/reperfusion phase?

In this context, ischemia refers to the period when blood flow to the heart is restricted, and reperfusion refers to the restoration of blood flow. The FOA highlights that reperfusion can paradoxically contribute to additional injury via multiple biological pathways, and it specifically aims to understand how hyperglycemia worsens injury across this sequence.

What mechanism of support does this opportunity use?

The mechanism of support is the NIH R01 Research Project Grant. Applicants are expected to propose a defined, hypothesis-driven research plan with clear aims, a strong preliminary rationale, and an approach consistent with a multi-year research project.

Is there a guaranteed number of awards or a guaranteed funding amount?

No. The solicitation does not promise a fixed number of awards or a guaranteed budget pool. Awards are contingent on the availability of funds and on receiving enough applications that are judged meritorious through NIH peer review.

What NIH program area does this fall under?

The program is geared toward cardiovascular disease research and is associated with CFDA 93.837.

Who is eligible to apply?

Eligibility is broad. The synopsis indicates eligible applicants include many domestic organization types such as state and local governments, tribal governments and tribal organizations, public and private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), independent school districts, special district governments, public housing authorities/Indian housing authorities, and for-profit entities including small businesses. Foreign institutions are also eligible to apply, as are eligible federal agencies, and faith-based or community-based organizations.

Are foreign institutions allowed to apply?

Yes. The eligibility statement indicates that foreign institutions are eligible to apply.

Can for-profit organizations or small businesses apply?

Yes. The eligibility statement includes for-profit entities, including small businesses.

Are state, local, or tribal governments eligible?

Yes. The eligibility list explicitly includes state and local governments as well as tribal governments and tribal organizations.

Are universities and colleges eligible?

Yes. Both public and private institutions of higher education are included in the eligibility list.

Are nonprofits eligible?

Yes. The eligibility list includes nonprofits, including 501(c)(3) organizations and certain non-501(c)(3) entities.

Is cost sharing or matching required?

No. The announcement notes there is no cost sharing or matching requirement.

What is the status of this funding opportunity?

This opportunity is archived. It originally had multiple receipt dates, with a final listed closing date of May 7, 2009, and an archive date of June 7, 2009. The archived status matters mainly for historical reference or for understanding how NIH previously structured calls in this research area.

Where can applicants find the full FOA text?

The administrative details reference an additional information link pointing to the full archived FOA text on the NIH grants website.

Who is listed as the sponsoring agency?

The sponsoring agency is the National Institutes of Health (NIH).

What contact route is mentioned in the synopsis?

The contact route provided is through the NIH Office of Extramural Research (OER) webmaster for access or linking problems. The synopsis suggests that scientific and programmatic contacts would typically be found within the full announcement, while the excerpted listing focuses on the public synopsis, eligibility, and timeline information.

What is the overall purpose or public health motivation of this FOA?

In plain terms, the FOA was designed to support rigorous, mechanistic cardiovascular research explaining how high blood sugar at the time of a heart ischemic event makes the heart more vulnerable to damage, and to push that understanding toward practical therapeutic strategies tested in preclinical settings. The underlying public health motivation is to improve outcomes after acute myocardial ischemia for patients who arrive with hyperglycemia by developing interventions that specifically blunt the added harm caused by elevated glucose during ischemia and reperfusion.